N-乙酰半胱氨酸对慢性阻塞性肺疾病急性加重的影响：一项荟萃分析与系统评价。
The effect of N-acetylcysteine on exacerbations of chronic obstructive pulmonary disease: A meta-analysis and systematic review.
作者信息
Fowdar Kaushal, Chen Huan, He Zhiyi, Zhang Jiujin, Zhong Xiaoning, Zhang Jianquan, Li Meihua, Bai Jing
机构信息
Department of Respiratory Medicine, The First Affiliated Hospital of Guangxi Medical University, Nanning 530021, PR China.
Department of Respiratory Medicine, The First Affiliated Hospital of Guangxi Medical University, Nanning 530021, PR China.
出版信息
Heart Lung. 2017 Mar-Apr;46(2):120-128. doi: 10.1016/j.hrtlng.2016.12.004. Epub 2017 Jan 18.
N-acetylcysteine (NAC) is an antioxidant and anti-inflammatory. Its effects on chronic obstructive pulmonary (COPD) outcomes, including exacerbation of and changes in lung function parameters, are controversial. To investigate the effects of NAC on COPD exacerbation and changes in lung function parameters in patients with COPD. A meta-analysis of randomized controlled trials retrieved from PubMed and Medline databases (12 trials; 2691 patients). High-dose [relative ratio (RR) = 0.90, 95% confidence interval (CI) = 0.82-0.996, P = 0.041] and low-dose (RR = 0.83, 95% CI = 0.69-0.99, P = 0.043) NAC reduced COPD exacerbation prevalence. Long-term (≥6 months), but not short-term, NAC reduced exacerbation prevalence (RR = 0.85, 95% CI = 0.74-0.98, P = 0.024). NAC did not affect exacerbation rate, forced expiratory volume in 1 s (FEV), forced vital capacity (FVC), or inspiratory capacity (IC). Long-term NAC therapy may reduce risk of COPD exacerbation.
N-乙酰半胱氨酸（NAC）是一种抗氧化剂和抗炎剂。其对慢性阻塞性肺疾病（COPD）相关结果的影响，包括病情加重和肺功能参数变化，存在争议。旨在研究NAC对COPD患者病情加重及肺功能参数变化的影响。对从PubMed和Medline数据库检索到的随机对照试验进行荟萃分析（12项试验；2691例患者）。高剂量[相对比率（RR）=0.90，95%置信区间（CI）=0.82 - 0.996，P = 0.041]和低剂量（RR = 0.83，95% CI = 0.69 - 0.99，P = 0.043）NAC可降低COPD病情加重的患病率。长期（≥6个月）而非短期使用NAC可降低病情加重的患病率（RR = 0.85，95% CI = 0.74 - 0.98，P = 0.024）。NAC对病情加重率、第1秒用力呼气容积（FEV）、用力肺活量（FVC）或吸气容量（IC）无影响。长期NAC治疗可能降低COPD病情加重的风险。
Zotero 插件